{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:04:57Z","timestamp":1768705497253,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.bone.2008.09.009","type":"journal-article","created":{"date-parts":[[2008,9,27]],"date-time":"2008-09-27T08:41:14Z","timestamp":1222504874000},"page":"160-167","source":"Crossref","is-referenced-by-count":32,"title":["Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK\/RANKL axis in osteolytic prostate cancer lesion in bone"],"prefix":"10.1016","volume":"44","author":[{"given":"Mandeep S.","family":"Virk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank A.","family":"Petrigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy Q.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arion F.","family":"Chatziioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Stout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine O.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Dougall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay R.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.bone.2008.09.009_bib1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar2169","article-title":"Tumor metastasis to bone","volume":"9","author":"Virk","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bone.2008.09.009_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1634\/theoncologist.5-6-463","article-title":"Management of bone metastases","volume":"5","author":"Coleman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2008.09.009_bib3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.eururo.2005.12.045","article-title":"Natural history and treatment of bone complications in prostate cancer","volume":"49","author":"Saad","year":"2006","journal-title":"Eur. Urol"},{"key":"10.1016\/j.bone.2008.09.009_bib4","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","article-title":"The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma","volume":"88","author":"Carlin","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2008.09.009_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.cr.7290266","article-title":"Mechanisms of cancer metastasis to the bone","volume":"15","author":"Yin","year":"2005","journal-title":"Cell Res."},{"key":"10.1016\/j.bone.2008.09.009_bib6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2008.09.009_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2004.11.070","article-title":"Crosstalk between cancer cells and bone microenvironment in bone metastasis","volume":"328","author":"Yoneda","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2008.09.009_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1023\/A:1015599831232","article-title":"Prostate carcinoma skeletal metastases: cross-talk between tumor and bone","volume":"20","author":"Keller","year":"2001","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bone.2008.09.009_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1677\/erc.0.0060333","article-title":"Factors regulating the growth of metastatic cancer in bone","volume":"6","author":"Boyce","year":"1999","journal-title":"Endocr.-Relat. Cancer"},{"key":"10.1016\/j.bone.2008.09.009_bib10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/cncr.11181","article-title":"Stromal factors involved in prostate carcinoma metastasis to bone","volume":"97","author":"Cooper","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2008.09.009_bib11","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2008.09.009_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bone.2008.09.009_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bone.2008.09.009_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1196\/annals.1346.013","article-title":"Regulation of osteoclast differentiation","volume":"1068","author":"Roodman","year":"2006","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bone.2008.09.009_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF03026317","article-title":"Roles for NF-kappaB and c-Fos in osteoclasts","volume":"23 Suppl","author":"Boyce","year":"2005","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2008.09.009_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0736-0266(02)00095-5","article-title":"Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone","volume":"21","author":"Lee","year":"2003","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bone.2008.09.009_bib17","first-page":"1637","article-title":"Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma","volume":"61","author":"Michigami","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2008.09.009_bib18","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.bjc.6600858","article-title":"Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis","volume":"88","author":"Ohshiba","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bone.2008.09.009_bib19","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1359\/jbmr.060706","article-title":"Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration","volume":"21","author":"Feeley","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.09.009_bib20","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.orthres.2005.05.004.1100230634","article-title":"The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone","volume":"23","author":"Whang","year":"2005","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bone.2008.09.009_bib21","first-page":"7883","article-title":"Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2008.09.009_bib22","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2106\/00004623-200206000-00022","article-title":"The role of growth factors in the repair of bone. biology and clinical applications","volume":"84-A","author":"Lieberman","year":"2002","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.bone.2008.09.009_bib23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/08977190412331279890","article-title":"Bone morphogenetic proteins","volume":"22","author":"Chen","year":"2004","journal-title":"Growth Factors"},{"key":"10.1016\/j.bone.2008.09.009_bib24","first-page":"389","article-title":"Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer","volume":"46","author":"Bobinac","year":"2005","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.bone.2008.09.009_bib25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.yexcr.2006.12.020","article-title":"Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells","volume":"313","author":"Deng","year":"2007","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bone.2008.09.009_bib26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jcb.10679","article-title":"Bone morphogenetic protein signaling in prostate cancer cell lines","volume":"91","author":"Brubaker","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bone.2008.09.009_bib27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/carcin\/bgg100","article-title":"The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells","volume":"24","author":"Langenfeld","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bone.2008.09.009_bib28","first-page":"89","article-title":"Differential expression and regulation of bone morphogenetic protein 7 in breast cancer","volume":"23","author":"Schwalbe","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bone.2008.09.009_bib29","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1158\/0008-5472.CAN-05-0289","article-title":"Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells","volume":"65","author":"Yang","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2008.09.009_bib30","first-page":"1129","article-title":"Bone morphogenetic proteins and their receptor signaling in prostate cancer","volume":"22","author":"Ye","year":"2007","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.bone.2008.09.009_bib31","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1359\/JBMR.050802","article-title":"Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer","volume":"20","author":"Feeley","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.09.009_bib32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bone.2005.07.015","article-title":"Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions","volume":"38","author":"Feeley","year":"2006","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2008.09.009_bib33","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2967\/jnumed.107.045666","article-title":"Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model with using 18F-FDG and 18F-Fluoride PET\/CT","volume":"49","author":"Hsu","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bone.2008.09.009_bib34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF02555045","article-title":"Distribution of fluoride concentration in the rat's bone","volume":"46","author":"Narita","year":"1990","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2008.09.009_bib35","first-page":"633","article-title":"Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET","volume":"33","author":"Hawkins","year":"1992","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bone.2008.09.009_bib36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4419-9129-4_7","article-title":"Opg, RANKl, and RANK in cancer metastasis: expression and regulation","volume":"118","author":"Brown","year":"2004","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.bone.2008.09.009_bib37","first-page":"49","article-title":"RANKL\/RANK\/OPG: new therapeutic targets in bone tumours and associated osteolysis","volume":"1704","author":"Wittrant","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bone.2008.09.009_bib38","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/pros.20744","article-title":"RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model","volume":"68","author":"Ignatoski","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.bone.2008.09.009_bib39","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature01245","article-title":"Structural basis of BMP signalling inhibition by the cystine knot protein Noggin","volume":"420","author":"Groppe","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bone.2008.09.009_bib40","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00259-002-0850-1","article-title":"Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease","volume":"29","author":"Berger","year":"2002","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bone.2008.09.009_bib41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0924-977X(02)00103-7","article-title":"Small animal PET","volume":"12","author":"Myers","year":"2002","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bone.2008.09.009_bib42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0952-7915(03)00066-9","article-title":"Micro-PET imaging and small animal models of disease","volume":"15","author":"Herschman","year":"2003","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bone.2008.09.009_bib43","doi-asserted-by":"crossref","first-page":"6285s","DOI":"10.1158\/1078-0432.CCR-06-0813","article-title":"Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis","volume":"12","author":"Vessella","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2008.09.009_bib44","doi-asserted-by":"crossref","first-page":"6305s","DOI":"10.1158\/1078-0432.CCR-06-1157","article-title":"Future treatment of bone metastases","volume":"12","author":"Lipton","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2008.09.009_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0b013e32805e8787","article-title":"Bone metastases in prostate cancer: a targeted approach","volume":"19","author":"Storey","year":"2007","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bone.2008.09.009_bib46","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.addr.2004.12.014","article-title":"Targeting of therapeutic agents to bone to treat metastatic cancer","volume":"57","author":"Bagi","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bone.2008.09.009_bib47","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.bjc.6603740","article-title":"Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer","volume":"96","author":"Duivenvoorden","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bone.2008.09.009_bib48","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1158\/0008-5472.CAN-06-3879","article-title":"In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer","volume":"67","author":"Banerjee","year":"2007","journal-title":"Cancer Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328208007801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328208007801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T11:54:52Z","timestamp":1545738892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328208007801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S8756328208007801"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2008.09.009","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}